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Retinoblastoma
Helen Dimaras, Kahaki Kimani, Elizabeth A O Dimba, Peggy Gronsdahl, Abby White, Helen S L Chan, Brenda L Gallie 
Retinoblastoma is an aggressive eye cancer of infancy and childhood. Survival and the chance of saving vision depend 
on severity of disease at presentation. Retino blastoma was the ﬁ rst tumour to draw attention to the genetic aetiology of 
cancer. Despite good under standing of its aetiology, mortality from retinoblastoma is about 70% in countries of low 
and middle income, where most aﬀ ected children live. Poor public and medical awareness, and an absence of rigorous 
clinical trials to assess innovative treatments impede progress. Worldwide, most of the estimated 9000 newly diagnosed 
patients every year will die. However, global digital communications present opportunities to optimise standards of 
care for children and families aﬀ ected by this rare and often devastating cancer. Parents are now leading the eﬀ ort for 
widespread awareness of the danger of leucocoria. Genome-level technologies could make genetic testing a reality for 
every family aﬀ ected by retinoblastoma. Best-practice guidelines, online sharing of pathological images, point-of-care 
data entry, multi disciplinary research, and clinical trials can reduce mortality. Most importantly, active participation of 
survivors and families will ensure that the whole wellbeing of the child is prioritised in any treatment plan.
Introduction
Retinoblastoma is the most common intraocular cancer 
of childhood. It is initiated by mutation of the RB1 gene, 
which was the ﬁ rst described tumour-suppressor gene.1,2,3 
Constitutional loss of one RB1 allele predisposes an 
individual to cancer; loss of the other allele from a 
developing retinal cell initiates development of retino-
blastoma tumours. This prototypic malignancy has 
transformed the thinking about cancer.
Incidence of retinoblastoma is constant worldwide at 
one case per 15 000–20 000 livebirths, which corresponds 
to about 9000 new cases every year.4 The disorder has no 
validated geographic or population hotspots. The greatest 
disease burden is recorded in large populations that have 
high birth rates, such as in Asia and Africa.4 In Nigeria, 
for example, retinoblastoma is the most common eye 
tumour,5 and is one of the ﬁ ve most frequent childhood 
malignancies.6 Regions with greatest prevalence have the 
highest mortality—40–70% of children with retino-
blastoma in Asia and Africa die, compared with 3–5% in 
Europe, Canada, and the USA (table 1).4,7,13,14,17,19
In Canada, mean age at diagnosis is 27 months (SD 18) 
for unilateral retinoblastoma18 and 15 months for bilateral 
disease (Gallie BL, unpublished). In Kenya, mean age at 
diagnosis is 36 months (SD 21·4) for unilateral retino-
blastoma, and 25 months (16·8) for bilateral disease.13 A 
delay of more than 6 months from the ﬁ rst clinical sign 
to diagnosis is associated with 70% mortality recorded in 
developing countries.
However, positive change is imminent, because genome 
science and global communications could allow all 
children and families aﬀ ected by retinoblastoma to have 
an equal opportunity for a cure. However, if welfare of the 
child is the main concern, to save life is more important 
than to save vision. In this Seminar, we draw attention to 
lessons learned about management of retinoblastoma 
and describe goals to ensure that all children with 
retinoblastoma receive the best possible life-saving and 
vision-saving care. We emphasise straightforward strat-
egies that can greatly improve the chances of survival and 
quality of life of children with retinoblastoma. 
Leucocoria
Leucocoria is the most common initial sign of retino-
blastoma (table 1),8,12,15,20,21 and is ﬁ rst apparent when the 
tumour is still contained within the eye. The life-
threatening white tumour reﬂ ects light and blocks view 
of the red retina (ﬁ gure 1). Retinoblastoma remains 
intraocular and curable for 3–6 months after the ﬁ rst 
sign of leucocoria. Leucocoria can also indicate other 
vision-threatening conditions—eg, Coats’ disease, cata-
ract, toxocariasis, retinopathy of prematurity—for which 
prompt medical attention is needed. It is ﬁ rst noticed by 
parents when the pupils of the child’s eyes dilate 
naturally in dim light, with a beam of light shining over 
the parents’ shoulder. Parents often have diﬃ  culty 
convincing health-care workers who see the child in 
bright surroundings of a problem. In a UK study,20 25% 
of children with leucocoria waited more than 4 weeks 
for primary-care referral to an ophthal mologist. Late 
diagnosis delays treatment, retinoblastoma spreads 
from the eye, and the chances of survival decrease.16 
Strabismus, poor visual tracking, glaucoma, and inﬂ am-
mation are other presenting signs (table 1).
Search strategy and selection criteria
We searched Medline for reports published between January, 
2005, and November, 2011, and their bibliographies with the 
terms “retinoblastoma tumour”, “retinoma”, “retinoblastoma 
genetic testing”, “retinoblastoma treatment”, and 
“retinoblastoma chemotherapy”. We included older, seminal 
publications that underpin understanding of retinoblastoma. 
We also used relevant review articles and best practice 
guidelines, although this Seminar is not focused on the 
epidemiology and clinical characteristics of retinoblastoma. 
We are part of the team that developed the Canadian 
Retinoblastoma Society’s guidelines for care. In developing 
these guidelines, we searched for all evidence-based sources; 
when none existed, we used consensus conferencing of 
multidisciplinary retinoblastoma experts, practitioners, 
survivors, and their families.
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Age at retinoblastoma diagnosis is a result of both the 
molecular basis—heritable retinoblastoma presents at a 
younger age than does non-heritable disease—and the 
medicosocial response to its symptoms and signs. The 
deadly eﬀ ect of delay is obvious in Africa and Asia, where 
proptosis (protrusion of the eye from the socket due to 
advanced spreading of tumour into the orbit) seems to be 
a common presentation.8–12 In these regions, socio-
economic factors and poor recognition of the seriousness 
of the disease impede access to care.24 Sadly, severe disease, 
the large numbers of infants, and overstressed health-care 
systems mean that children suﬀ er when early detection 
and straightforward surgical treatment could have cured 
the disorder.
Flash photography can enable early detection of 
leucocoria (ﬁ gure 1).25 Anecdotal evidence suggests that 
parents who notice this photoleucocoria now commonly 
search the internet and promptly seek medical attention. 
A retinoblastoma education campaign in Honduras 
showed that public awareness led to early detection.16 The 
nationwide awareness campaign led by the Kenyan 
National Retinoblastoma Strategy group is educating the 
public and health-care workers about implications 
of leucocoria.26,27 Eﬀ ectiveness of campaigns will be 
validated when their short-term and long-term eﬀ ects on 
severity of disease at presentation are measured.
RB1 mutation status
Alfred Knudson advanced understanding of cancer when 
he analysed the long-known fact that children unilaterally 
aﬀ ected by retinoblastoma are diagnosed at an older age 
than are bilaterally aﬀ ected children, and formulated the 
hypothesis that two hits (mutational events) are rate-
limiting for the development of retinoblastoma.3 David 
Comings expanded the notion to include malig nancy-
suppressing loci, recognising that Knudson’s hits might 
be mutations inactivating both copies of a retina-speciﬁ c 
gene.1 The discovery of the RB1 gene at chromosome 
13q14 in the 1980s conﬁ rmed that RB1 was the ﬁ rst 
tumour-suppressor gene.2,28,29
Loss of function of RB1 initiates retinoma and causes 
genomic instability,30 but is insuﬃ  cient to cause retino-
blastoma. The genomic instability probably leads to 
changes in other genes.31 The event that triggers malignant 
proliferation after mutation of RB1 is un known. Although 
Comings assumed that the retino blastoma-causative gene 
would be retina-speciﬁ c,1 RB1 loss in many other human 
cancers can contribute to cancer progression, presumably 
by loss of cell-cycle control and genomic stability.32–35
In both heritable and non-heritable retinoblastoma, 
biallelic mutations of the RB1 tumour-suppressor gene 
initiate tumour growth (ﬁ gure 2). In heritable retino-
blastoma, the ﬁ rst RB1 mutation (M1) is constitutional, 
predisposing the child to retinal tumours. Somatic 
mutations (M2) in one or more retinal cells initiate 
tumour growth (ﬁ gure 2). Very rarely, primitive neuro-
ectodermal tumours arise in the pineal or suprasellar 
region, leading to trilateral retinoblastoma. 
All bilateral retinoblastoma is heritable, but only a 
small proportion of unilateral disease can be passed on to 
future generations (table 2). Most children with heritable 
retinoblastoma carry a novel mutation not detected in the 
Mean age at diagnosis (months) Mortality (%) Cases with diﬀ erent ﬁ rst presenting signs (%)
Unilateral Bilateral Leucocoria Proptosis Swelling Strabismus Hypopyon
Europe
All countries7 ·· ·· 5–11% ·· ·· ·· ·· ··
Asia
Malaysia8 ·· ·· ·· ·· 22% ·· ·· ··
Taiwan9 27 16 36% 78% 17% ·· 13% ··
Africa
Mali10 ·· ·· ·· ·· 55% ·· ·· ··
Nigeria11 31 15 ·· 62% 85% 30% ·· 46%
Eastern Africa12 36 24 ·· 56% 30% 28% 11% ··
Kenya13 36 25 73% ·· ·· ·· ·· ··
North America
Mexico14 31 20 11% ·· ·· ·· ·· ··
USA15 25 13 ·· 56% ·· <1% 24% ··
Canada 27* 15† 1%‡ ~80%‡ 0%‡ ·· ·· ··
Central America
Honduras16 ·· ·· 35–73% 54–83% ·· ·· ·· ··
South America
Brazil17 ·· ·· 5–22% 79% ·· 10% 11% ··
*Taken from Mallipatna et al.18 †Gallie BL, unpublished. ‡Taken from Canadian Retinoblastoma Society guidelines.19
Table 1: Geographical variation in age at diagnosis, mortality, and ﬁ rst presenting sign
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parents. 1% of the children who carry the mutation 
(which might or might not have been inherited) do not 
develop retinoblastoma tumours (unaﬀ ected carriers; 
table 2), although their oﬀ spring who inherit the mutation 
(50%) are at risk.
A constitutional RB1 mutation also imposes an in-
creased risk of second malignancies of the lung, bladder, 
bone, soft tissues, skin, and brain throughout life, 
especially when the children are treated with radiation.37 
New constitutional mutations arise mostly in a parental 
germ cell, usually paternal.38,39 Less frequently, the RB1 
mutation arises in one cell of the multicell embryo, 
resulting in mosaicism in the proband.40 Heritable 
retinoblastoma results, but antecedent relatives are not at 
risk, because mosaicism is not inherited. 
Various mutations inactivate the 27 exon RB1 gene, most 
of which are unique to a family, suggesting a high rate of 
new mutation. M1 and M2 RB1 mutations include the full 
range of deleterious mutations: point mutations, small 
and large deletions, and deep intronic and splice mutations. 
The M2 mutation is identical to the M1 mutation in 52% 
of tumours.36 Methylation (addition of a methyl group at 
CpG sites) of the promoter is a common M1 or M2 event 
in somatic cells, but is only a constitutional M1 event when 
a translocation leads to transcriptional silencing.36,41
Figure 1: Progression of retinoblastoma from small intraretinal tumours to massive orbital retinoblastoma probably extending into the brain 
Progression of retinoblastoma (A) from small intraretinal tumours that can be cured by laser treatment and cryotherapy (TNM T1a, IIRC A) to massive orbital 
retinoblastoma probably extending into the brain (TNM T4a-b). A diﬀ erence in age at diagnosis recorded between Canada and Kenya could be the diﬀ erence between 
possible cure and certain death (B). The Canadian child with leucocoria was diagnosed because of the left-hand image, which was taken by his sister with his mother’s 
mobile phone. TNM=Tumor Node Metastasis Cancer Staging.22 IIRC=the International Intraocular Retinoblastoma Classiﬁ cation.23
T1a T1b T2a T2b, T3a T3b T4a,b,c,d
A
TNM
IIRC B C D E
A
B
Delay in diagnosis
Canada Kenya
Figure 2: Genetics of heritable and non-heritable retinoblastoma
N=normal. RB1+/+=two normal RB1 alleles. M1=constitutional RB1 mutation. 
RB1+/-=one mutated, one normal RB1 allele. M2=somatic RB1 mutation. 
RB1-/-=two mutated RB1 alleles. 
N
N
M1
M1/M2
M2
All cells predisposed Tumour
RB1+/–RB1+/+ RB1–/–
Tumour
RB1–/–RB1+/+
Heritable retinoblastoma
Non-heritable retinoblastoma
 Heritable Not heritable Total
Bilateral retinoblastoma 40 0 40
Inherited 5 0 ··
Not inherited 35 0 ··
Unilateral retinoblastoma 7 52 59
Inherited 1 0 ··
Not inherited 6 0 ··
Unaﬀ ected carrier 1  0 1
Data taken from Richter et al.36
Table 2: Genetic status of 100 children with the retinoblastoma 
genotype or phenotype, or both 
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Most RB1 mutations result in an inactive retinoblastoma 
protein (pRB).40 Compared with completely inactive pRB, 
partly inactive pRB reduces penetrance (fewer aﬀ ected 
gene carriers) and expressivity (fewer tumours in those 
aﬀ ected, with more unilaterally aﬀ ected).42,43 Children 
with loss of RB1 and ﬂ anking genes because of large 
deletions on chromosome 13q can also have develop-
mental anomalies (eg, facial dysmorphia, congenital 
abnormalities, mental retardation, and motor impair-
ment).44,45 Children with large deletions including RB1 
have fewer tumours than do those with the common null 
mutations, perhaps because an unknown adjacent 
deleted gene is essential for tumour-cell survival.46,47 
Presumably, cells in which M1 and M2 mutations delete 
such an essential gene will die, and tumours would form 
only when M2 is a diﬀ erent mutation so that the cell has 
a normal copy of the essential gene.
Molecular genetic testing for RB1 mutations has 95% 
sensitivity.40 The risk that oﬀ spring will inherit the mutant 
RB1 from the aﬀ ected parent is 50%, which would result 
in a 97% risk of retinoblastoma and high lifelong risk 
of other cancers. The American Society for Clinical 
Oncology recommends that genetic testing be oﬀ ered 
when family history suggests genetic suscep tibility to 
cancer and when testing will aﬀ ect manage ment.48 
Screening for RB1 mutations at any stage of pregnancy 
can be done once the familial RB1 mutation is known 
(panel). Infants who carry their family’s RB1 mutation 
have such high risk of retinoblastoma that guidelines 
from the Canadian Retinoblastoma Society19 recommend 
obstetrical care and premature delivery (at 36 weeks’ 
gestation) to allow best possible early treatment of small 
tumours. Early detection of small-volume tumours and 
timely intervention with focal laser treatment and 
periocular topotecan often cures the disorder (ﬁ gure 3), 
and the patient develops good vision with minimum 
morbidity.49 Young relatives (oﬀ spring, siblings, and ﬁ rst 
cousins) who do not carry the family’s mutation can 
avoid repeated invasive surveillance pro cedures under 
anaesthesia.36,50 The M1 or M2 RB1 mutations are also 
useful tumour biomarkers to detect any residual disease 
in cerebrospinal ﬂ uid and bone marrow before a 
supralethal-dosage chemotherapy regimen or autologous 
peripheral haemopoietic stem-cell transplant is used.51
Genetic testing for RB1 is the standard of care in Canada 
and other countries,19 but is not available in developing 
countries. Detection of the novel RB1 mutation in a 
proband costs around US$3000. High-sensitivity mole-
cular diagnosis substantially reduces health-care and 
family expenses and improves the quality of care.36,50 Next-
generation-sequencing technologies promise reduced 
costs because of high eﬃ  ciency. A so-called global-to-local 
model of health service would directly connect forefront 
genomic science with local teams. Regional clinical 
laboratories would validate genomic results and test at-risk 
family members, and local health-care workers would use 
the knowledge to improve health care for probands and 
their families. Local teams would gain scientiﬁ c and 
clinical skills with access to global standards and validated 
technologies, participation in peer certiﬁ cation, and oppor-
tunities for regional, socially responsible entrepre neur-
ship. This shift in genomic diagnostic clinical translation 
could become broadly relevant to health care.
Genetic progression of retinoblastoma
Although RB1 loss means that a susceptible retinal cell 
can become malignant, it only produces retinoma, the 
benign precursor of retinoblastoma.30,52 Retinoma is 
identiﬁ ed in 5% of individuals, either incidentally or 
because they have a child with retinoblastoma.52 However, 
retinoma is also recorded in 16% of eyes enucleated 
because of retino blastoma,30 suggesting that it is a 
common precursor of retinoblastoma. Non-proliferative 
retinomas show loss of RB1, and low-level genomic 
instability—ie, extra copies of genes on chromosome 1q, 
including the motor protein, KIF14, and the regulator of 
apoptosis, MDM4.30 Highly proliferative retinoblastomas 
show high-level genomic instability,53 with increased 
copies of the oncogenes KIF14, DEK, E2F3, and MYCN, 
and loss of the tumour-suppressor gene CDH11.54 What 
causes a benign retinoma to become a malignant 
retinoblastoma could be accumulation of genomic 
instability, or an as-yet unidentiﬁ ed event.30 All cancers 
are associated with somatic mutations, and investigators 
Panel: One family’s history of retinoblastoma
The father was born in 1968 and survived because both eyes 
with retinoblastoma were removed before he was 3 years old. 
His son was born in 1996, 10 days post-term. One eye was 
removed, but the tumours in his other eye were successfully 
treated with chemotherapy, focal laser treatment, and 
cryotherapy. The daughter was tested before her birth in 1999, 
because the precise germline null RB1 mutation of her father 
and brother was known to be an 11 bp deletion on exon 14. 
She was electively delivered at 36 weeks’ gestation, and her 
ﬁ rst tumour in the left eye (ﬁ gure 3) was treated immediately 
with focal laser treatment only. All 12 tumours in her eyes were 
successfully treated with only focal laser treatment and 
cryotherapy, resulting in excellent vision in each eye.
Figure 3: Progression of retinoblastoma
At 36 weeks’ gestation (A), one small tumour was present in the left eye (white circle). Scars from laser treatments 
remain, sparing the fovea and vision (B).
2001
VA 6/6
A B
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are doing whole-genome sequencing of cancers to 
identify mutations that cause malignancy.55 Such cancer 
genes could promote tumour growth, aggressiveness, 
resistance to therapy, and metastasis.
Medical management of retinoblastoma
Clinical classiﬁ cation
Classiﬁ cation of the extent of cancer at presentation is 
fundamental for assessment of prognosis, prediction of 
outcomes, initial treatment, and most importantly 
improve ment of therapy through rigorously conducted 
clinical trials.23 The ﬁ rst classiﬁ cation of intraocular 
retinoblastoma by Reese and Ellsworth56 predicted the 
outcome of external-beam radiotherapy. When the high 
risk of secondary malignancy induced by radiation in 
children with constitutional RB1 mutations was identiﬁ ed 
in the 1980s, chemotherapy replaced radiotherapy.57,58 The 
International Intraocular Retinoblastoma Classi ﬁ cation 
(IIRC) for prediction of outcomes for eyes treated with 
chemotherapy and focal laser treatment was accepted at 
the 2003 meeting of the International Society of Genetic 
Eye Disease and Retinoblastoma.23
A consistent clinical staging system is essential to enable 
communication and assess outcomes. However, ad-hoc 
changes in clinical criteria for each stage have made the 
IIRC inconsistent in some studies,59,60 even within the 
Children’s Oncology Group.59 These discrepancies danger-
ously undermine the prognostic value of the IIRC, leading 
to both overtreatment and undertreatment. Patients’ lives 
could be jeopardised if enucleation is delayed by attempts 
to cure eyes with high-risk features (eg, orbital cellulitis, 
hyphaema, media opacity, neovascular glaucoma, tumour 
anterior to the retina, suspicious optic nerve, or suspected 
extraocular disease on imaging), so that the tumour 
spreads extraocularly when prompt surgery would have 
cured the disease. Adverse features and microscopic 
extraocular spread of the tumour requiring intensive 
treatment can be accurately assessed only by histopathology 
of the high-risk eye.59,60
We recommend IIRC classiﬁ cation of each eye by 
extent of intraocular disease at diagnosis, and use of the 
seventh edition of the American Joint Committee on 
Cancer and International Union Against Cancer’s staging 
(TNM clinical classiﬁ cation) to assess the whole patient 
by extent of extraocular disease.22 TNM is the gold-
standard classiﬁ cation to establish an appropriate care 
plan for patients with cancer. Because TNM is used 
world wide (subject to regular revisions based on accumu-
lated evidence) and is enforced by an international expert 
committee, ophthalmology journals now recom mend 
use of the cTNM classiﬁ cation system for staging of 
retinoblastoma.61 
Enucleation
A deﬁ nitive cure for intraocular retinoblastoma is 
achieved by removal of the eye before the tumour 
spreads.62 Prompt removal of high-risk eyes showing 
signs of potential tumour spread (eg, orbital cellulitis, 
poor view of the inside of the eye, bleeding inside the 
eye, neovascular glaucoma, tumour anterior to the 
retina, suspicious optic nerve, or suspected extraocular 
disease on imaging) will cure most children. The 
secondary goal to save vision of patients with bilateral 
retinoblastoma who would otherwise become blind—
might necessitate chemotherapy with focal laser treat-
ment and cryotherapy, or as a last resort radio therapy. 
However, successful treatment of bilaterally aﬀ ected 
children has meant that similar treatment has been 
given to unilaterally aﬀ ected children instead of primary 
enucleation, who could die because of delays to removal 
of the high-risk eye.62 Although unilateral cTNM cT1a or 
b (IIRC A and B) eyes could be saved with recovery of 
useful vision, to salvage a severely aﬀ ected unilateral 
eye might not be in the best interest of a child with one 
normal eye.18 Timely enucleation reduces risk of 
metastatic spread, morbidity, side-eﬀ ects of chemo-
therapy and focal laser treatment, and repeated examin-
ations under anaesthesia.
Care must be taken when eyes with intraocular 
retinoblastoma are enucleated, because the tumour 
could spread. Orbital implants are important for sub-
sequent bone growth and a good cosmetic appearance. 
The myoconjunctival technique, in which the surgeon 
places a simple, inexpensive plastic (polymethyl 
methacrylate) implant posteriorly in the orbit, and 
attaches rectus muscles to the conjunctival fornices, 
results in excellent movement of the prosthesis, as 
shown in a randomised study.63 Risk of orbital disease is 
not a reason to avoid an implant, because imaging and 
treatment of orbital recurrence can be treated without 
interference from the implant.
Some useful vision can be salvaged in eyes of some 
unilaterally aﬀ ected children when tumours are small by 
expensive and invasive treatment. These therapies are 
not available in most countries of low and middle 
income. No child with unilateral intraocular disease 
should lose his or her chance of a cure, or die from 
metastases, because delayed removal of a severely 
aﬀ ected eye allows extraocular spread.
Commonly, families reject enucleation as curative 
treatment because of perceived social stigma and poor 
understanding of the high quality of life after unilateral 
enucleation, or when they falsely believe that other 
treatments oﬀ ered far from home might save the eye. 
With appropriate support, even children who lose both 
eyes to retinoblastoma can go on to lead full and highly 
productive lives.
Histopathology of enucleated eyes
Careful histopathological examination of enucleated 
eyes is essential to conﬁ rm or rule out metastatic spread 
(ﬁ gure 4). Eyes are graded according to the pTNM 
pathology classi ﬁ cation.22 Detailed examination of 
pathological changes in the enucleated eye is crucial to 
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assess risk of tumour spread, and identiﬁ es whether 
adjuvant postoperative treatment or metastatic surveil-
lance is necessary.18 Late removal of clinical stage cT3 
(IIRC E) eyes (ie, still clinically intraocular), because 
chemotherapy given before enucle ation results in a 
false reduction or masking of the pathological staging, 
induces complacency about the risk of extra ocular 
disease, and increases mortality.62 When the optic nerve, 
choroid, or both are shown to be involved, curative 
adjuvant treatment and metastatic surveillance is 
recommended. By the time extraocular disease is 
clinically obvious, cure is very diﬃ  cult.64 When extra-
ocular disease is already present at diagnosis, inten-
sive treatment is necessary to attempt to save the 
child’s life.
A worldwide issue is poor access to comprehen-
sive retinoblastoma pathology. Long-delayed inaccurate 
pathology reports impede development of a rational 
management plan. In the absence of accurate pathology, 
doctors could discharge children perceived to be cured 
by surgery alone without follow-up surveillance, or pro-
ceed with unnecessary postoperative adjuvant chemo-
therapy in a well meaning, but misguided approach to 
the patient.
In Kenya, an experiment is under way to address this 
problem (ﬁ gure 4).26,27 The Retinoblastoma Collaborative 
Laboratory Service will receive specimens or sections of 
eyes and provide detailed reports based on standard 
operating procedures approved by the Kenyan National 
Retinoblastoma Strategy. Scanned slides will be reviewed 
on the internet, providing feedback to clinicians to 
support rational treatment decisions. This experiment 
will measure the eﬀ ect of timely, accurate pathology 
reports on survival and quality of life.
Figure 4: Histology of removed eyes and Kenyan collaborative project
The features in the eye removed because of retinoblastoma that suggest risk of spread outside the eye include: (A) invasion of the choroid; and (B) tumour extension 
into the optic nerve. Microscopic slides can be scanned and viewed online, supporting multidisciplinary management irrespective of geography. For example, in the 
Kenyan RB Collaborative Laboratory project (C), patients are referred (arrows) to centres focusing on retinoblastoma, in which histology slides are prepared and 
scanned for shared management on the internet. 
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Clinical trials
The guidelines from the Canadian Retinoblastoma 
Society19 and an attempted meta-analysis65 draw atten tion 
to the absence of class A evidence from randomised 
clinical trials to guide treatment. As a result, consensus 
recommendations and current practice at retino blastoma 
centres are the basis for these guidelines. Clinical trials 
are the gold standard for evidence-based care, because 
they ascertain utility, eﬃ  cacy, and safety of new methods. 
Because retino blastoma is rare, few clinical trials have 
been completed. A search of ClinicalTrials.gov on 
Nov 12, 2011, yielded 57 results, of which 22 trials are 
investigating the eﬃ  cacy of a treatment speciﬁ cally 
targeted to patients with retino blastoma (table 3). Only 
six are multicentre trials, with most participating centres 
in high-income countries. Middle-income countries are 
not widely represented (ﬁ ve of 19 studies), and no 
investigations are occurring in low-income countries. As 
shown in other paediatric cancers, rigorous multicentre 
trials led by multi disciplinary teams will most eﬀ ectively 
improve care for all children with the disorder.
Systemic chemotherapy for intraocular retinoblastoma 
most commonly consists of carboplatin, etoposide, and 
vincristine.67 The Toronto Protocol58,67,68 combines short 
courses of high-dose chemotherapy and simultaneous, 
high-dose but short-duration ciclosporin to target 
multidrug resistance without incurring increased 
chemotoxicity. Short courses of chemotherapy reduce 
risk for short-term and long-term toxic eﬀ ects. The 
Toronto Protocol is being studied in an international, 
multicentre clinical trial (NCT00110110; table 3). Even 
long-term systemic chemotherapy alone cannot be relied 
on to control intraocular retinoblastoma. The good initial 
responses must be consolidated with focal laser treatment 
or cryotherapy, or both.67,69 Close surveillance with this 
treatment at frequent examinations under anaesthesia is 
necessary for 2 years or longer after chemotherapy to 
ensure ablation of all tumour cells and establish a cure.
External-beam radiotherapy was ﬁ rst used to treat 
retinoblastoma in the early 1950s.70 Only 40 years later was 
it fully recognised that radiation greatly heightens lifelong 
risk of second cancers for a child with a constitutional RB1 
mutation.37,68,71,72 Retrospective studies37,68,71,72 have shown 
that irradiated retinoblastoma survivors develop secondary 
cancers as soon as 10 years after diagnosis, a risk that 
persists throughout life. If radiotherapy had been studied 
through a formal clinical trial with mandated long-term 
follow-up, this grave danger might have been recognised 
much sooner, and many deaths would have been 
prevented. Chemotherapy combined with focal laser 
treatment has replaced radiotherapy as primary treatment, 
mostly because of radiotherapy’s long-term oncogenic 
eﬀ ects in individuals with constitutional RB1 mutations.
Stereotactic or conformal radiation73—given in ways that 
minimise dose to bone and soft tissues—is mainly used 
for the remaining eye after chemotherapy, focal laser 
treatment, and brachytherapy have all failed. These new 
methods reduce cosmetic deformities associated with 
radiotherapy in young children. However, the long-term 
oncogenic eﬀ ects of stereotactic and conformal radiation 
will not be known for many years. Other potential long-
term eﬀ ects of stereotactic radiation on the endocrine 
system (such as growth hormone), eyes (tearing, cornea, 
lens, retina), skin, soft tissues, bone, and brain tissue are 
unknown. A formal clinical trial with mandatory long-
term follow-up would be informative about oncogenic 
potential and other possible long-term side-eﬀ ects.
As with radiotherapy, many treatments for retino-
blastoma have been adopted without evidence of 
eﬀ ectiveness, complications, outcomes, or cost. Clinical 
trials are now starting that have rigorous eligibility criteria, 
predeﬁ ned outcome measures, exclusion criteria, and 
assessment of adverse events. For example, few eﬃ  cacy 
data are available for local periocular carboplatin,74 but 
orbital morbidity has already been reported.75,76 A phase 1 
study66 of an achievable dose of periocular topotecan 
(NCT00460876; table 3) in patients with relapsed or 
resistant bilateral retinoblastoma showed low systemic 
toxicity, but did not establish tumour responses.
Intra-arterial chemotherapy was used to treat retino-
blastoma in 187 patients in Japan between 1988 and 
2001.77 However, the investigators initially described only 
technical success, without eﬃ  cacy or toxicity data. Some 
follow-up data were reported in October, 2011.78 Ophthal-
mic arterial infusion of melphalan is technically feasible 
and can result in striking regression of tumour.79–81 These 
optimistic reports do not specify eligibility criteria, 
control of retinoblastoma, vision achieved, or survival 
rates of the eye or patient. Three single-institution studies 
could provide these important data (NCT01151748, 
NCT00906113, and NCT00857519; table 3). Meanwhile, 
as with the worldwide adoption of radiotherapy in the 
1950s, intra-arterial chemotherapy is being widely used 
outside of formal studies.82,83
Disseminated leptomeningeal disease is the most 
diﬃ  cult type of extraocular retinoblastoma to cure. The 
craniospinal radiation doses and volumes necessary for 
adequate treatment of leptomeningeal retinoblastoma 
are too toxic for young children. Radiotherapy causes 
growth, intellectual, cognitive, and endocrine comorbid-
ities, particularly in children younger than 3 years.84 Bone 
marrow, other metastatic sites, and disease in the 
cerebrospinal ﬂ uid might be cured with: systemic 
chemotherapy (with intraventricular chemotherapy for 
disease of the cerebrospinal ﬂ uid); complete surgical 
excision of accessible metastatic disease; or autologous 
peripheral haemopoietic stem-cell rescue of the marrow 
after supralethal-dose chemotherapy, with85,86 or without64 
orbital and metastatic-site radiotherapy. These treatments 
are rarely available in developing countries.
Cure of trilateral disease, especially with leptomeningeal 
spread, is also rare, but is possible.87–89 When diagnosis of 
trilateral retinoblastoma can be made on the basis of 
retinal ﬁ ndings and CT or MRI of intracranial disease, 
For ClinicalTrials.gov see http://
clinicaltrials.gov
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Phase Study group Treatment Date ﬁ rst 
registered
Primary 
sponsor
Subsites Date 
completed
Completed
NCT00002675 2 Patients with 
retinoblastoma
Carboplatin, etoposide, and 
vincristine; cisplatin; 
cyclophosphamide
May, 1995 NY, USA No Jan, 2001
NCT00002794 2 Intraocular bilateral or 
multifocal unilateral 
retinoblastoma
Carboplatin and vincristine Feb, 1996 TN, USA No Oct 3, 2011
NCT00004006 2 Extrachoroidal or 
metastatic retinoblastoma, 
or both
Carboplatin and etoposide; 
cyclophosphamide; topotecan; 
doxorubicin; radiotherapy; ABMT
Nov 1, 1997 TN, USA No Oct 1, 2011
NCT00079417 3 IIRC group B eyes Neoadjuvant carboplatin/
vincristine; FT, with or without 
brachytherapy
Dec, 2005 NCI/COG USA Jan, 2010
NCT00901238 1/2 Advanced unilateral or 
bilateral retinoblastoma
Intra-arterial melphalan May 1, 2006 NY, USA No Jul 1, 2009
NCT0046087666 1 Relapsed bilateral 
retinoblastoma
Periocular topotecan March, 2007 Argentina No April, 2008
Active, not yet recruiting
NCT00073384 3 Intraocular retinoblastoma Carboplatin, etoposide, and 
vincristine; subtenon carboplatin; 
FT
Nov 4, 2003 NCI/COG USA ··
NCT00360750 ·· Advanced enucleated 
retinoblastoma
Carboplatin, etoposide, and 
vincristine; cytarabine, with or 
without radiotherapy
Sept, 2005 CCLG UK ··
NCT00179920 2 Intraocular germline 
retinoblastoma
Carboplatin; etoposide; FT Sept 12, 2005 IL, USA No ··
NCT00186888 3 Intraocular retinoblastoma Individualised treatment* Sept 12, 2005 TN, USA No ··
NCT00335738 3 Enucleated retinoblastoma Carboplatin, etoposide, and 
vincristine for high-risk disease; 
observation for no risk 
Dec, 2005 NCI/COG USA, Canada, 
Australia, India, 
New Zealand
··
Recruiting
NCT00110110 2 Bilateral IIRC group B, C, or 
D eyes
Carboplatin, etoposide, and 
vincristine; CSA; FT (Toronto 
Protocol)
June, 2004 ON, Canada Canada, 
Singapore, 
India, Chile
··
NCT00432445 2 Intraocular and periocular 
retinoblastoma
PBR Feb 5, 2007 TX, USA No ··
NCT00554788 3 Extraocular retinoblastoma Carboplatin, etoposide, and 
vincristine; thiotepa, cisplatin, 
cyclophosphamide, radiotherapy, 
ASCT
Feb, 2008 NCI/COG USA, Canada, 
Australia, 
Argentina, 
Egypt, India†
··
NCT00857519 ·· Advanced unilateral/
bilateral retinoblastoma
Intra-arterial melphalan; 
intra-arterial carboplatin
Jan, 2009 PN, USA No ··
NCT00889018 ·· IIRC group C and D eyes Comparison of two diﬀ erent doses 
of subtenon carboplatin
April 27, 2009 Delhi, India No ··
NCT00906113 1/2 Patients with 
retinoblastoma
Intra-arterial melphalan May 19, 2009 Israel No ··
NCT00980551 Bilateral retinoblastoma Vincristine and topotecan; 
subconjunctival carboplatin
Sept 18, 2009 OH, USA No ··
NCT01393769 2 Unilateral IIRC group D eyes Intra-arterial melphalan Nov 1, 2009 Spain No ··
NCT01293539 2 Intraocular retinoblastoma Intra-arterial melphalan March 1, 2011 MD, USA No ··
NCT01466855 ·· Intraocular retinoblastoma Intra-arterial melphalan Oct 19, 2011 OH, USA No ··
Not yet recruiting
NCT01151748 2 IIRC group D and E eyes Intra-arterial chemotherapy Sept, 2010 CA, USA No ··
ABMT=autologous bone-marrow transplant. IIRC=International Intraocular Retinoblastoma Classification. FT=focal laser treatment. NCI= National Cancer Institute. 
COG=Children’s Oncology Group. CCLG=Children’s Cancer and Leukemia Group. CSA=ciclosporin A. PBR=proton-beam radiation. ASCT=autologous stem-cell 
transplant. *Including: enucleation; vincristine and carboplatin; FT; external-beam radiotherapy; vincristine and topotecan; vincristine, carboplatin, and etoposide; 
vincristine, cyclophosphamide, and doxorubicin; and periocular carboplatin. †These subsites were not listed on the database, but were reported as subsited by the trial 
principal investigator. 
Table 3: Clinical trials of retinoblastoma treatment listed on ClinicalTrials.gov grouped by status
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biopsy of the intracranial tumour should be avoided 
because it might jeopardise the chance of cure.90
In view of the reality that many children in countries of 
low and middle income worldwide die of retinoblastoma, 
palliative-care protocols are urgently needed. Chemo-
therapy provides good palliation of gross orbital disease. 
Radiotherapy could provide symptomatic relief.91 Until 
extraocular disease can be substantially reduced 
worldwide by early diagnosis and treatment, clinical 
studies are also necessary to optimise palliation. 
Extraocular retino blastoma is rarely recorded in high-
income countries, but is very common in countries of 
low and middle income (table 1). 
Follow-up
Follow-up is deﬁ ned as the period after the last active 
disease is detected. During short-term follow-up, the 
child is monitored for recurrence of primary retino-
blastoma; in long-term follow-up, all patients with 
heritable RB1 mutations, or who have undergone 
chemotherapy, external-beam radiotherapy, or autologous 
peripheral haemopoietic stem-cell transplant are 
monitored for second primary tumours.19 Long-term 
side-eﬀ ects of chemotherapy with autologous peripheral 
haemopoietic stem-cell transplant, including risk of 
second cancers, are not well documented. Meta-analyses 
are not informative because every child is essentially 
treated ad hoc. The rate of second malignancies in 
retinoblastoma survivors with low penetrance or mosaic 
RB1 mutations is unknown, but is presumed to be lower 
than that in those with constitutional null RB1 alleles.
Family support
Support programmes provide assistance and help 
families to cope with the many stresses associated with 
retinoblastoma. Abandonment of therapy is the main 
cause of treatment failure in curable children in countries 
of low and middle income, apparently because of limited 
resources and a perceived stigma of cancer or loss of an 
eye. The emerging online networks of families who assist 
each other to cope and locate essential services and 
resources might improve the situation. Families in 
countries of low and middle income could, however, 
remain isolated from such support.
Because families in these countries increasingly learn 
about eye-salvage treatments in high-income coun tries, 
they might seek alternatives to enucleation. For all 
children, treatment as close to home as possible is the best 
approach. Delays and poor follow-up associated with 
attempts to seek care internationally too often result in 
preventable death. The ﬁ nancial and psychological 
burdens of international care aﬀ ect families for many 
years after treatment. An honest, realistic approach to the 
child’s whole wellbeing, including liaison with the local 
medical team, could best achieve appropriate care and the 
child’s best chance of survival with good quality of life.
Complexity of care
Retinoblastoma is best managed by a multidisciplinary 
team, including but not limited to ophthalmologists, 
oncologists, paediatric nurses, imaging specialists, 
pathologists, pharmacists, child-life specialists, and social 
workers.19 An electronic medical-record system designed 
speciﬁ cally to capture data relevant to retinoblastoma 
could help to manage the complexity of care. eCancerCare 
is a point-of-care medical-record database based on 
consensus practice guidelines, which summarises 
medical history in visual timelines (ﬁ gure 5).92 The 
system allows continued professional development of 
the multidisciplinary team, improves communication, 
and promotes adherence to care guidelines and research. 
The graphical timelines make treatment and outcomes 
easy to understand for both health-care workers and 
parents, irrespective of language and education.92 
Conclusions
A worldwide network dedicated to children and families 
aﬀ ected by retinoblastoma is emerging. The internet 
will help in many ways: parent-to-parent support can 
be established, shared care can be assisted by the 
eCancerCare database and digital pathology, and 
multicentre clinical trials could obtain class A evidence 
for care. Internet communications are changing the care 
for children with retinoblastoma, and allow clinicians to 
aspire to equal access to evidence-based care for all 
children with retinoblastoma.
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Figure 5: eCancerCare database
The disease-speciﬁ c electronic patient illustrated clinical timeline (DePICT) displays all treatments since diagnosis 
of retinoblastoma. Point-of-care data entry, digital drawings, images of tumours, and details of events can be 
viewed online in the database, within the health institution or in a national database. 
Time (years)
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Time since diagnosis
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